Drugs in phase I and II clinical development for the prevention of stroke in patients with atrial fibrillation. (2021)
Attributed to:
Maximising patient benefit: Leeds’ Interdisciplinary approach to translation
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1080/13543784.2021.1897786
PubMed Identifier: 33682570
Publication URI: http://europepmc.org/abstract/MED/33682570
Type: Journal Article/Review
Volume: 30
Parent Publication: Expert opinion on investigational drugs
Issue: 10
ISSN: 1354-3784